Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Headache Disorders, Primary Clear all
Completed Phase 3 Interventional Results available

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months

NCT00792103
View directory record Official record
Conditions
Migraine Disorders
Interventions
NP101
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Newport Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 27, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Results available

Maximizing Outcomes in Treating Acute Migraine

NCT03896009
View directory record Official record
Conditions
Migraine
Interventions
AXS-07 (MoSEIC meloxicam and rizatriptan), Meloxicam, Rizatriptan, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
85
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 27, 2026, 10:14 PM EDT
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Migraine Headaches

NCT04211454
View directory record Official record
Conditions
Migraine
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 27, 2026, 10:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines

NCT01953341
View directory record Official record
Conditions
Migraine
Interventions
AMG 333, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Sep 27, 2026, 10:14 PM EDT
Completed No phase listed Observational Results available

A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.

NCT06532357
View directory record Official record
Conditions
Migraine
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 27, 2026, 10:14 PM EDT
Completed No phase listed Observational Results available

Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine

NCT06412965
View directory record Official record
Conditions
Migraine Disorders
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Sep 27, 2026, 10:14 PM EDT
Active, not recruiting Not applicable Interventional

Treatment for Migraine and Mood

NCT05576467
View directory record Official record
Conditions
Migraine, Depressive Symptoms
Interventions
MBCT-Telephone, MBCT-Video, Enhanced Usual Care (EUC)
Behavioral
Lead sponsor
Amanda Shallcross
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
The Bronx, New York • Winston-Salem, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 27, 2026, 10:14 PM EDT
Completed Phase 3 Interventional

Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea

NCT00329459
View directory record Official record
Conditions
Migraine Disorders
Interventions
sumatriptan succinate/naproxen sodium, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
34
States / cities
Mesa, Arizona • Little Rock, Arkansas • Fair Oaks, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2016 · Synced Sep 27, 2026, 10:14 PM EDT
Recruiting Not applicable Interventional

A Feasibility Trial of Virtual Reality Neurofeedback for Adolescents With Migraine

NCT07454798
View directory record Official record
Conditions
Migraine, Headache Disorders, Primary
Interventions
Immersive Neurofeedback Self-Regulation Training (INSeRT), Virtual Reality Imagery (No Neurofeedback)
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
10 Years to 16 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 27, 2026, 10:14 PM EDT
Completed Not applicable Interventional

Heartmath Migraine Study

NCT04077658
View directory record Official record
Conditions
Migraine
Interventions
HeartMath, Waitlist Control
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Sep 27, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Acute Migraine Headache in Children

NCT00355394
View directory record Official record
Conditions
Migrainous Headache
Interventions
Metoclopramide, Placebo
Drug · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 29, 2015 · Synced Sep 27, 2026, 10:14 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

NCT06417775
View directory record Official record
Conditions
Migraine
Interventions
Ubrogepant, Placebo for Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
103
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 27, 2026, 10:14 PM EDT
Recruiting Phase 3 Interventional

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

NCT04743141
View directory record Official record
Conditions
Acute Treatment of Migraine
Interventions
Rimegepant (PF-07899801)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
115
States / cities
Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 77 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 27, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Results available

Greater Occipital Nerve Block With Bupivacaine for Acute Migraine

NCT02665273
View directory record Official record
Conditions
Migraine
Interventions
Greater occipital nerve block, Bupivacaine
Procedure · Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 27, 2026, 10:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults

NCT02609945
View directory record Official record
Conditions
Migraine
Interventions
zolmitriptan, CVT-427 (zolmitriptan inhalation powder),
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Sep 27, 2026, 10:14 PM EDT
Completed Phase 4 Interventional Results available

Metoclopramide Versus Ketorolac for Tension-type Headache

NCT01011673
View directory record Official record
Conditions
Headache
Interventions
Metoclopramide, Ketorolac
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 27, 2026, 10:14 PM EDT
Withdrawn Phase 1 Interventional

Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache

NCT04353505
View directory record Official record
Conditions
Chronic Migraine, Cluster Headache, Trigeminal Neuralgia
Interventions
Ketorolac, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Sep 27, 2026, 10:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine

NCT00846495
View directory record Official record
Conditions
Migraine
Interventions
topiramate, frovatriptan
Drug
Lead sponsor
Clinvest
Individual
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Oviedo, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Sep 27, 2026, 10:14 PM EDT
Recruiting Not applicable Interventional

Cocoa Extract for Migraine Trial

NCT06808230
View directory record Official record
Conditions
Migraine
Interventions
Cocoa extract, Cocoa extract placebo
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 27, 2026, 10:14 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Acute Treatment Trial in Adult Subjects With Migraines

NCT03872453
View directory record Official record
Conditions
Migraine
Interventions
Zavegepant, Zavegepant matching placebo, Intranasal Aptar Pharma Unit Dose System
Drug · Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
82
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Sep 27, 2026, 10:14 PM EDT
Completed Phase 4 Interventional Results available

A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine

NCT00335777
View directory record Official record
Conditions
Migraine
Interventions
Migranal nasal spray at 1 hour, Migranal nasal spray at 4 hour
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Sep 27, 2026, 10:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

NCT05337254
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Dihydroergotamine
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 27, 2026, 10:14 PM EDT
Completed No phase listed Observational

Machine Learning Assessment of Next-Day Migraine Likelihood

NCT07227194
View directory record Official record
Conditions
Migraine
Interventions
Not listed
Lead sponsor
Theranica
Industry
Eligibility
8 Years and older
Enrollment
53,065 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 27, 2026, 10:14 PM EDT
Withdrawn Phase 2 Interventional

Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine

NCT03280342
View directory record Official record
Conditions
Migraine, Headache
Interventions
IR-TPM (Topamax), XR-TPM (Trokendi XR)
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Sep 27, 2026, 10:14 PM EDT